Abstracts tagged "Systemic sclerosis"

Abstract Number: 0702 • ACR Convergence 2025
Effectiveness of Oral Anticoagulants in Precapillary Pulmonary Hypertension Associated with Systemic Sclerosis: a EUSTAR Cohort Study.
Nicola Farina¹, Silvia Bellando-Randone², hilde Bjørkekjær³, David Launay⁴, Patricia E. Carreira⁵, paolo airò⁶, Serena Guiducci⁷, Dilia Giuggioli⁸, Gabriela Riemekasten⁹, carmen-Pilar Simeón Aznar¹⁰, Christina Bergmann¹¹, Elise Siegert¹², Ivan Castellví¹³, Lesley Ann Saketkoo¹⁴, Jeska de Vries-Bouwstra¹⁵, Dr. Philipp Klemm¹⁶, ulf Müller-Ladner¹⁷, Alexandra Balbir- Gurman¹⁸, Vanessa Smith¹⁹, Florenzo Iannone²⁰, Luca Idolazzi²¹, Christopher Denton²², edoardo rosato²³, Britta Maurer²⁴, Yannick Allanore²⁵, Yoshiya Tanaka²⁶, elisabetta zanatta²⁷, Marie-Elise Truchetet²⁸, Masataka Kuwana²⁹, Mickaël MARTIN³⁰, Alberto Cauli³¹, Kamal Solanki³², Francesco Del Galdo³³, Ana Maria Gheorghiu³⁴, Branimir Anic³⁵, Gábor Kumánovics³⁶, Gonçalo Boleto³⁷, Kristofer Andréasson³⁸, Simona Rednic³⁹, Lorinda Chung⁴⁰, susana Oliveira⁴¹, marius cadar⁴², Francesco Paolo Cantatore⁴³, Carolina de Souza Müller⁴⁴, Vivien Hsu⁴⁵, Yair Levy⁴⁶, Gianluca Moroncini⁴⁷, Jörg Henes⁴⁸, Andra Balanescu⁴⁹, and Ellen De Langhe⁵⁰, , Carlomaurizio Montecucco⁵¹, Petros Sfikakis⁵², Michele Iudici⁵³, Stefan Heitmann⁵⁴, Madelon Vonk⁵⁵, Anna-Maria Hoffmann-Vold⁵⁶, Oliver Distler⁵⁷, Marco Matucci-Cen⁵⁸, Cosimo Bruni⁵⁷, ¹Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, Milan, Italy, ²University of Florence, Florence, Florence, Italy, ³Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, olso, Norway, ⁴Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U¹²⁸⁶ - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, ⁵Hospital Universitario ¹² de Octubre, Madrid, Spain, ⁶Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, brescia, Italy, ⁷Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, Pistoia, Italy, ⁸Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, Modena, Italy, ⁹University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ¹⁰Hospital Universitario Vall d'Hebron Passeig, Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Barcelona, Spain, Zaragoza, Spain, ¹¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ¹²Charité University Hospital, Department of Rheumatology, Berlin, Germany, Berlin, Germany, ¹³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, barcelona, Spain, ¹⁴University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, ¹⁵Leiden University Medical Center, Leiden, Netherlands, ¹⁶Kerckhoff-Klinik Bad Nauheim, Berlin, Germany, ¹⁷JLU Giessen, Campus Kerckhoff, Department of Rheumatology and Clinical Immunology Center, Bad Nauheim, Germany, Bad Nauheim, Germany, ¹⁸Rambam Health Care Campus, Rheumatology Institute, Haifa, Israel, israel, Israel, ¹⁹Ghent University Hospital, Gent, Belgium, ²⁰Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ²¹Section of Rheumatology, Department of Medicine, University of Verona, Verona, Italy, verona, Italy, ²²University College London, UK, London, United Kingdom, ²³Sapienza University of Rome, Department of Translational and Precision Medicine Azienda Ospedaliero-Universitaria Policlinico Umberto ¹-Centro di riferimento regionale per la sclerosi sistemica, Rome, Italy, rome, Italy, ²⁴Department of Rheumatology & Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, ²⁵Université Paris Cité, Paris, France, ²⁶University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²⁷Padova University Hospital, Rheumatology Unit, Padova, Italy, padova, Italy, ²⁸Bordeaux University Hospital, Bordeaux, France, ²⁹Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ³⁰Poitiers University Hospital, Department of Internal Medicine, Poitiers, France, MIGNALOUX-BEAUVOIR, France, ³¹Rheumatology Unit, Department of Medicine and Public Health, AOU and University of Cagliari, Cagliari, Italy, ³²Waikato Hospital, Hamilton, New Zealand, ³³University of Leeds, Leeds, United Kingdom, ³⁴Spitalul Clinic Dr. Ion Cantacuzino, Bucharest, Romania, ³⁵University of Zagreb, School of Medicine, University Hospital Center Zagreb, Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Zagreb, Croatia, zagreb, Croatia, ³⁶University of Pécs, Department Of Rheumatology And Immunology, Medical Centre, Pecs, Hungary, Pecs, Hungary, ³⁷Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Rheumatology Department, Lisbon, Portugal, Paris, France, ³⁸Skåne University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ³⁹University of Medicine and Pharmacy Iuliu Hatieganu Cluj, Clinica Reumatologie, Cluj-Napoca, Romania, Cluj-Napoca, Romania, ⁴⁰Stanford University, Stanford, CA, ⁴¹Fernando Fonseca Hospital, Department of Medicine IV, Systemic Immunomediated Diseases Unit, Amadora, Portugal, amadora, Portugal, ⁴²Sapienza University of Rome, Rheumatology Clinic, Rome, Italy, Rome, Italy, ⁴³University of Foggia, Department of Medical and Surgical Sciences, Rheumatology Unit, Foggia, Italy, foggia, Italy, ⁴⁴Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Brazil, curitiba, Brazil, ⁴⁵Rutgers- RWJ Medical School, South Plainfield, NJ, ⁴⁶Meir Medical Center, Kfar-Saba, Israel, Kefar Sava, Israel, ⁴⁷Department of Internal Medicine, Marche University Hospital, Clinica Medica, Ancona, Italy, Ancona, Italy, ⁴⁸Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany, ⁴⁹UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, ⁵⁰University Hospital Leuven, Laboratory of Tissue Homeostasis and Disease, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, Leuven, Belgium, ⁵¹Università di Pavia e IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy, ⁵²NKUA - SCHOOL OF MEDICIN, Athens, Greece, ⁵³Division of Rheumatology, Department of Internal Medicine Specialties, Geneva University Hospitals, Geneva, Switzerland, ⁵⁴Department of Rheumatology, Marienhospital Stuttgart, Böheimstrasse 37, D-70199 Stuttgart, Germany, ⁵⁵Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵⁶Oslo University Hospital, Oslo, Norway, ⁵⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁵⁸University San Raffaele Milano, Milano, Italy

Background/Purpose: Precapillary pulmonary hypertension (PH) in systemic sclerosis (SSc) associates with severe morbidity and mortality. The prothrombotic state observed in idiopathic pulmonary arterial hypertension (PAH)…
Abstract Number: 0674 • ACR Convergence 2025
Quantitative Imaging in Systemic Sclerosis Patients Receiving Sodium Thiosulfate for Calcinosis Cutis
Ian Odell¹, Crystal Cheung¹, Megan Wu², Stephanie Perez³, Agrani Dixit⁴, Cassandra van Horn³, Muhammad Hamdan⁵, Baran Gunes⁶, Sophia Kujawski⁷, Hyojeong Lee³, Annie Wang³, Denise Esserman⁸, Michael Zamani⁹, F. Perry Wilson³, John Onofrey³, Xenophon Papademetris³ and Monique Hinchcliff¹⁰, ¹Yale University School of Medicine, New Haven, CT, ²Yale University School of Medicine, Greenville, ³Yale University School of Medicine, New Haven, ⁴Yale School of Medicine, New Haven, CT, ⁵Yale University School of Medicine, Mansfield, ⁶Yale University School of Medicine, Pompton Plains, NJ, ⁷The George Washington University, New Haven, CT, ⁸Yale University School of Public Health, New Haven, ⁹Independent Statistician, Washington D.C., ¹⁰Yale School of Medicine, Westport, CT
Background/Purpose: Calcinosis cutis (CC) is a disabling skin condition associated with systemic sclerosis (SSc). Although many CC treatments including sodium thiosulfate (STS) have been proposed,…
Abstract Number: 0809 • ACR Convergence 2025
Human blood vessel organoids as a model of vasculopathy in systemic sclerosis
Yanhua Xiao¹, Xuezhi Hong¹, Langxian Zhi¹, Yi-Nan Li², Martin Regensburger³, Franz Marxreiter⁴, Boris Görg⁵, Sarah Koziel⁶, Andrea-Hermina Györfi⁷, Tim Filla⁸, Peter-Martin Bruch⁶, Philipp Tripal⁹, James Adjaye¹⁰, Sascha Dietrich¹¹, Jürgen Winkler⁴, Jörg Distler¹² and Alexandru-Emil Matei¹³, ¹Medical Faculty of Heinrich Heine University, Dusseldorf, Germany, ²University Hospital of Düsseldorf, Düsseldorf, Germany, ³Department of Stem Cell Biology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Germany, ⁴Department of Molecular Neurology, FAU Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Germany, ⁵Heinrich-Heine University, Dusseldorf, Germany, ⁶University Hospital Düsseldorf, Dusseldorf, Germany, ⁷Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁸Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁹University Hospital Erlangen, FAU Erlangen-Nürnberg, Erlangen, ¹⁰Institute for Stem Cell Research and Regenerative Medicine, University Hospital Düsseldorf, Moorenstrasse ⁵, D-⁴⁰²²⁵ Duesseldorf, Germany, Dusseldorf, Germany, ¹¹Heinrich Heine University Duesseldorf, University Hospital Duesseldorf, Duesseldorf, Germany, ¹²University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany
Background/Purpose: While several pathogenic processes involved in vasculopathy in systemic sclerosis (SSc) have been described1-3, the mechanisms that underlie the SSc microvasculopathy remain incompletely understood.…
Abstract Number: L18 • ACR Convergence 2024
CCL19+ Fibroblasts Orchestrate Fibrotic Microenvironment via CCL19-CCR7 Axis in Systemic Sclerosis
Wei Guo¹, Zhaohua Li², Dan Xu² and Rong Mu², ¹Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China, ²Peking University Third Hospital, Beijing, China
Background/Purpose: Understanding the roles of diverse fibroblast subsets is of great importance in elucidating the pathogenesis of fibrosis in systemic sclerosis (SSc). However, how the…
Abstract Number: 0706 • ACR Convergence 2024
Single Center Prospective Cohort of Systemic Sclerosis Patients Who Are At-Risk for Pulmonary Hypertension
Carleigh Zahn¹, Scott Visovatti², Rosemary Gedert¹, Suiyuan Huang¹, Victor Moles¹, Amber Young¹, Vallerie McLaughlin¹ and Dinesh Khanna¹, ¹University of Michigan, Ann Arbor, MI, ²The Ohio State University, Columbus
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of mortality in systemic sclerosis (SSc). We launched an IRB approved prospective study (NOVEL) in 2013 at…
Abstract Number: 0958 • ACR Convergence 2024
TCR Motifs Identify Unique Clones in African Americans with Systemic Sclerosis
Urvashi Kaundal¹, Chloe Borden², Devin Teehan², Brittany Dulek³, Justin Lack⁴, Ami Shah⁵, Maureen Mayes⁶, Daniel Shriner⁷, Ayo P. Doumatey⁷, Amy Bentley⁷, Robyn Domsic⁸, Thomas Medsger, Jr⁹, Paula Ramos¹⁰, Richard Silver¹¹, Virginia Steen¹², John Varga¹³, Vivien Hsu¹⁴, Lesley Ann Saketkoo¹⁵, Dinesh Khanna¹³, Elena Schiopu¹⁶, Jessica Gordon¹⁷, Lindsey Criswell¹⁸, Heather Gladue¹⁹, Chris Derk²⁰, Elana Bernstein²¹, S. Louis Bridges¹⁷, Victoria Shanmugam²², Lorinda Chung²³, Suzanne Kafaja²⁴, Reem Jan²⁵, Marcin Trojanowski²⁶, Avram Goldberg²⁷, Benjamin Korman²⁸, Faiza Naz²⁹, Stefania Dell'Orso³⁰, Adebowale Adeyemo⁷, Elaine Remmers³¹, Charles Rotimi⁷, Fredrick Wigley³², Francesco Boin³³, Daniel Kastner³⁴ and Pravitt Gourh²⁹, ¹Scleroderma Genomics and Health Disparities Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Chevy Chase, MD, ²Scleroderma Genomics and Health Disparities Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Integrated Data Science Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ⁴Integrated Data Science Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, Bethesda, MD, ⁵Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁶UTHealth Houston Division of Rheumatology, Houston, TX, ⁷Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁹Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Verona, PA, ¹⁰Medical University of South Carolina, Charleston, SC, ¹¹Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ¹²Georgetown University School of Medicine, Washington, DC, ¹³University of Michigan, Ann Arbor, MI, ¹⁴Department of Medicine, Rheumatology Division, Rutgers-RWJ Medical School, South Plainfield, NJ, ¹⁵New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University and Tulane University Medical Schools, New Orleans, LA, ¹⁶Division of Rheumatology, Medical College of Georgia at Augusta University, Martinez, GA, ¹⁷Division of Rheumatology, Weill Cornell Medical College, New York, NY, ¹⁸Genomics of Autoimmune Rheumatic Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, Bethesda, MD, ¹⁹Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²⁰Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²¹Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, ²²NIH Office of Autoimmune Disease Research in the Office of Research on Women's Health, National Institutes of Health, Bethesda, MD, Bethesda, MD, ²³Stanford University, Woodside, CA, ²⁴Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ²⁵Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL, ²⁶Department of Rheumatology, Boston University School of Medicine, Boston, MA, ²⁷NYU Langone Health - NYU Hospital for Joint Diseases, Lake Success, NY, ²⁸University of Rochester, Rochester, NY, ²⁹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ³⁰Genomic Technology Section, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³¹Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³²Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, ³³Cedars-Sinai Medical Center, Los Angeles, CA, ³⁴National Human Genome Research Institute, Bethesda, MD
Background/Purpose: Systemic sclerosis (SSc) is a rare multisystem autoimmune disease that disproportionately affects African Americans (AA). Previous work from our lab has suggested a pivotal…
Abstract Number: 1561 • ACR Convergence 2024
Association of Large Vessel Vasculitis and Development of SSc and SSc-Associated Antibodies: Impact of Pulmonary Arterial Hypertension
Brett Dinner¹, Ahmed Abdelmaksoud², Ann Igoe³, Taylor Viggiano⁴ and Vivek Nagaraja⁵, ¹Creighton University, Paradise Valley, AZ, ²University of California, Riverside, Riverside, CA, ³Flow, Tempe, AZ, ⁴Mayo Clinic, Phoenix, ⁵Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Large vessel vasculitis (LVV) comprises a spectrum of rare, potentially life-threatening disorders, including giant cell arteritis (GCA) and Takayasu's arteritis (TAK), defined by granulomatous…
Abstract Number: 1587 • ACR Convergence 2024
Predictors of Body Mass Index in an Early Systemic Sclerosis Cohort
Ali Ayla¹, Meng Zhang¹, Claudia Pedroza², Bingrui Chen², Brian Skaug¹, Maureen Mayes¹, Shervin Assassi¹ and Zsuzsanna McMahan¹, ¹UTHealth Houston Division of Rheumatology, Houston, TX, ²UTHealth Houston, Houston, TX
Background/Purpose: Malnutrition is a significant problem among patients with systemic sclerosis (SSc). Body mass index (BMI) is often low in patients with malnutrition. Low BMI…
Abstract Number: 1824 • ACR Convergence 2024
Skin Macrophage Subtypes and Impact of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis: Results from Single-cell Analyses of an Observational Data Set and a Phase I/II Randomized Controlled Trial
Juliette Ferrant¹, Alain Lescoat², Valérie Lecureur³, Marie Lelong³, John Varga⁴, Robert Lafyatis⁵, Johann Gudjonsson⁴ and Dinesh Khanna⁴, ¹CHU Rennes, Rennes, France, ²CHU Rennes - University Rennes 1, Rennes, France, ³Rennes University, Rennes, France, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Macrophages play a major role in dcSSc-related skin fibrosis, with a mixed M1-M2 activation profile relying on the activation of JAK/STAT. Tofacitinib, a pan-JAK…
Abstract Number: 2207 • ACR Convergence 2024
Improvement Across Physician and Patient Reported Outcome Measures over a 24 Months-time Period in the Juvenile Systemic Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Ozgur Kasapcopur³, Amra Adrovic⁴, Kathryn Torok⁵, Maria Teresa Terreri⁶, Ana Sakamoto⁷, Jordi Anton⁸, Brian Feldman⁹, Raju Khubchandani¹⁰, Tadey Avcin¹¹, Sindhu R. Johnson¹², Mikhail Kostik¹³, Edoardo Marrani¹⁴, Flavio Sztajnbok¹⁵, Maria Katsicas¹⁶, Dana Nemcova¹⁷, Maria Jose Santos¹⁸, Simone Appenzeller¹⁹, Cristina Battagliotti²⁰, Lillemor Berntson²¹, Jürgen Brunner²², Liora Harel²³, Gerd Horneff²⁴, Tilmann Kallinich²⁵, Kirsten Minden², Farzana Nuruzzaman²⁶, Anjali Patwardhan²⁷, Dieneke Schonenberg-Meinema²⁸ and Nicola Helmus²⁹, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁴Cerrahpasa Medical School, Istanbul, Turkey, ⁵Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ⁶UNIFESP, São Paulo, SP, Brazil, ⁷Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil, ⁸Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ⁹Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ¹⁰SRCC Childrens Hospital, Mumbai, India, ¹¹University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ¹²University of Toronto, Toronto, Canada, ¹³Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ¹⁴University of Florence, Firenze, Florence, Italy, ¹⁵UFRJ/UERJ, SAO PAULO, Brazil, ¹⁶Hospital Garrahan, Buenos Aires, Argentina, ¹⁷MD, Prague, Czech Republic, ¹⁸Hospital Garcia de Orta and Centro Académico de Medicina de Lisboa, Lisboa, Portugal, ¹⁹Unicamp, Campinas, SP, Brazil, ²⁰Hospital de Niños Dr Orlando Alassia, Santa Fe, Argentina, ²¹Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ²²Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ²³Faculty of Medicine, Tel Aviv University, Tel Aviv; Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, Petach Tikva, HaMerkaz, Israel, ²⁴Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ²⁵Charite, Berlin, Germany, ²⁶Stony Brook Children's Hospital, Stony Brook, NY, ²⁷University of Missouri-Columbia, Department of Child Health, 404 N Keene Street, Columbia MO 65210, Columbia, ²⁸Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ²⁹Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1 000 000 children. The Juvenile Systemic Scleroderma Inception cohort…
Abstract Number: 2470 • ACR Convergence 2024
Progression Patterns in Systemic Sclerosis – Associated Interstitial Lung Diseases
anais Roeser¹, Pierre-Yves Brillet¹, Marouane Boubaya¹, Frédéric Caux¹, Robin Dhote¹, Hilario Nunes¹ and Yurdagül Uzunhan², ¹APHP, Bobigny, France, ²Service de Pneumologie, Hôpital Avicenne, AP-HP, Bobigny, France
Background/Purpose: The occurrence of interstitial lung disease (ILD) in the course of systemic sclerosis (SSc) is associated with increased morbidity and mortality. SSc-ILD evolution is…
Abstract Number: 0247 • ACR Convergence 2024
Enhanced Immunogenicity of the Recombinant Herpes Zoster Vaccine After One-Week of Mycophenolate Mofetil Discontinuation in Patients with Autoimmune Rheumatic Diseases: Interim Results from a Prospective Randomized Phase 4 Study
Sandra Pasoto¹, Isabele Antonelli¹, Ana Cristina Medeiros-Ribeiro², Nadia Aikawa³, Leonard Kupa¹, Eduardo Borba¹, Luciana Seguro⁴, Emily Figueiredo Neves Yuki¹, ANA PAULA ASSAD¹, Carla Saad⁴, Andrea Shimabuco⁴, Andrea Negrini¹, Julia Medeiros¹, Talita Ribeiro¹, Samuel Shinjo⁴, Percival Sampaio-Barros⁴, Danieli Andrade⁵, Fernando Souza⁴, Renata Miossi⁴, Clovis Silva⁶ and Eloisa Bonfa¹, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil, ³Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁵University of São Paulo, São Paulo, SP, Brazil, ⁶Rheumatology Division and Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil
Background/Purpose: Recently, it was demonstrated that temporarily halting mycophenolate mofetil (MMF) for 1-week post-COVID-19 vaccination in systemic lupus erythematosus (SLE) patients improved humoral response, without…
Abstract Number: 0707 • ACR Convergence 2024
Comprehensive Skin Assessment in Systemic Sclerosis Using Spatial Frequency Domain Imaging (SFDI)
Hung Vo¹, Aarohi Mehendale², Mahendra Chaudhari³, Fatima El adili³, Jeffrey Browning⁴, Michael York⁵, Marcin Trojanowski⁶, Eugene Kissin⁷, Darren Roblyer² and Andreea Bujor⁵, ¹Boston Medical Center, Peabody, MA, ²Department of Biomedical Engineering, Boston University, Boston, MA, ³Boston Medical Center, Boston, MA, ⁴Boston University, Cambridge, MA, ⁵Boston University, Boston, MA, ⁶Department of Rheumatology, Boston University School of Medicine, Boston, MA, ⁷Boston University, Newton, MA
Background/Purpose: The modified Rodnan skin score (mRSS) is the gold standard for scleroderma (SSc) skin assessment, yet it suffers from subjectivity and interrater variability. Spatial…
Abstract Number: 0959 • ACR Convergence 2024
Radiomics Non-Invasively Conveys Time-Resolved Molecular Pathway Activity in Experimental Fibrosing Interstitial Lung Disease
David Lauer¹, Matthias Brunner², Hubert Gabrys³, Kerstin Klein², Oliver Distler⁴, Britta Maurer⁵ and Janine Gote-Schniering², ¹University Hospital Bern, Bern, Switzerland, ²University of Bern, Bern, Switzerland, ³University Hospital Zurich, Zurich, Zurich, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ⁵University Hospital Bern, University Bern, Bern, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is a major cause of mortality in patients with autoimmune-related CTD such as SSc and RA. Molecular characterization of the…
Abstract Number: 1565 • ACR Convergence 2024
Prevalence and Risk Factors of Lower Extremities Arterial Disease in Systemic Sclerosis: Preliminary Data from a Single Centre Multidisciplinary Study
Maria-Grazia Lazzaroni¹, Paolo Baggi², Liala Moschetti¹, Eleonora Pedretti³, Elda Piovani¹, Claudia Barison¹, Emma Manzoni⁴, Franco Franceschini¹, Stefano Bonardelli² and Paolo Airò¹, ¹Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ²Vascular Surgery Unit, ASST Spedali Civili of Brescia, University of Brescia, Italy, Brescia, Italy, ³Scleroderma Unit, Rheumatology Unit, ERN ReCONNET, ASST Spedali Civili and University of Brescia; Italy, Brescia, Italy, ⁴University of Brescia, Brescia, Italy
Background/Purpose: Microvascular changes represent a key step of pathogenic process in Systemic Sclerosis (SSc). However, SSc has been demonstrated to carry an increased risk of…

« Previous Page
1
…
8
9
10
11
12
…
56
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].